Clinical Trials Logo

HIV Infections clinical trials

View clinical trials related to HIV Infections.

Filter by:

NCT ID: NCT01964937 Withdrawn - HIV Infections Clinical Trials

Evaluating the Safety and Immune Response to Five Different Combinations of HIV Vaccines in Healthy, HIV-Uninfected Adults

Start date: n/a
Phase: Phase 1
Study type: Interventional

This study will evaluate the safety and immune response to five different combinations of three HIV vaccines in healthy, HIV-uninfected adults.

NCT ID: NCT01956396 Completed - HIV Infections Clinical Trials

Evaluation of Safety and Efficacy of the PrePexTM Device for Rapid Scale up of Adult MC Programs in Zimbabwe

ZW-01
Start date: October 2011
Phase: Phase 1
Study type: Interventional

The protocol, approved by the Medical Research Council, was issued to assess the safety and efficacy of the non-surgical device for applying it to the national scale up of adult male circumcision in Zimbabwe

NCT ID: NCT01953653 Completed - HIV Infection Clinical Trials

Feasibility of Using a Structured Daily Diary

Start date: February 2013
Phase: N/A
Study type: Interventional

This protocol explores the feasibility and acceptability of using two daily diary methods to analyze state-dependent variables and psychosocial health outcomes in Human Immunodeficiency Virus (HIV)-positive young men who have sex with men (YMSM). The study will explore the potential of diaries for use in feedback-based interventions.

NCT ID: NCT01949116 Completed - HIV Infections Clinical Trials

Safety and Effectiveness of Low-Dose Methotrexate for Reducing Inflammation in HIV-Infected Adults on ARV Medications

Start date: January 31, 2014
Phase: Phase 2
Study type: Interventional

People with HIV infection who are taking antiretroviral therapy (ART) could be at risk for cardiovascular disease (CVD), which can be caused by inflammation. Methotrexate (MTX) is a medication used to treat inflammation in people with rheumatoid arthritis. This study evaluated the safety and effectiveness of low-dose methotrexate (LDMTX) at reducing inflammation in HIV-infected adults.

NCT ID: NCT01946217 Completed - HIV Infection Clinical Trials

Factors Affecting Patient Participation in AIDS Malignancy Clinical Trials Consortium Clinical Trials

Start date: September 2013
Phase: N/A
Study type: Observational

This pilot research trial studies factors affecting patient participation in Acquired Immune Deficiency Syndrome (AIDS) Malignancy Clinical Trials Consortium clinical trials. Determining how patients makes decisions about participating in a clinical trial may help doctors plan clinical trials in which more patients are willing to participate and are satisfied with their decision to participate.

NCT ID: NCT01944371 Completed - HIV Clinical Trials

Short-term Disulfiram Administration to Reverse Latent HIV Infection: a Dose Escalation Study

Start date: September 2013
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine the safety, pharmacology and bioactivity of disulfiram in antiretroviral treated HIV-infected adults. The investigators primary hypothesis is that 3 days of disulfiram will result in an increase in HIV transcription in CD4+ T-cells in patients on suppressive antiretroviral therapy (ART).

NCT ID: NCT01942655 Completed - HIV Reservoirs Clinical Trials

IL-23/IL-12 Imbalance and T Lymphocyte Polarization in HIV Infection

INTESTIPAX
Start date: June 1, 2014
Phase: N/A
Study type: Interventional

Progressive HIV or HIV infection seems to be related to a preferential loss of CD4+ T lymphocytes, especially Th17+, within the mucosal intestinal lymphoid tissue, and with intestinal mucosal damage and bacterial product translocation, which correlates with the hyperactivation of the immune system, therefore with CD4+ T cell loss and prognosis. The objectives of this project are to investigate the correlation between the IL12/IL-23 imbalance and bacterial product translocation, and to study the polarization, infection or depletion of intestinal Th17 ex vivo. The investigators will test the effect of neutralizing anti-IL23 antibodies directed against p40, or less classically, anti- IL-23 p19.

NCT ID: NCT01939197 Completed - Chronic Hepatitis C Clinical Trials

A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection

TURQUOISE-I
Start date: August 30, 2013
Phase: Phase 2/Phase 3
Study type: Interventional

The primary objectives of this study are to assess the safety of ABT-450/r/ABT-267 with and without ABT-333 coadministered with and without ribavirin (RBV) for 12 and 24 weeks in HCV GT1- or 4-infected participants with HIV-1 coinfection and to evaluate the percentage of subjects achieving HCV ribonucleic acid (RNA) < lower limit of quantification (LLOQ) 12 weeks following treatment.

NCT ID: NCT01937455 Active, not recruiting - HIV Infections Clinical Trials

A Phase 1, Randomized, Blinded, Dose-escalation Study of rAAV1-PG9DP Recombinant AAV Vector Coding for PG9 Antibody in Healthy Male Adults.

Start date: September 2014
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability and immunogenicity of rAAV1-PG9DP when administered intramuscularly at different dose levels in healthy male adults.

NCT ID: NCT01934803 Completed - HIV Infection Clinical Trials

Zinc for HIV Disease Among Alcohol Users - an RCT in the Russia ARCH Cohort

ZINC
Start date: October 2013
Phase: N/A
Study type: Interventional

This study is a double-blinded randomized controlled trial (RCT) to assess the efficacy of zinc supplementation vs. placebo among 250 HIV-infected Russians from the Russia ARCH Cohort, who are ART-naive at enrollment and have a recent history of heavy drinking.